Tesamorelin + Ipamorelin (Blend)
/ Two-component vendor blend — tesamorelin (long-acting GHRH analog) plus ipamorelin (selective GHS-R1a agonist hexapeptide)ALIAS · Tesa/IPA blend · Tesamorelin/Ipamorelin stack
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4 for the combination. Each component independently has clinical data — tesamorelin is FDA-approved for HIV-associated lipodystrophy (Egrifta, 2010); ipamorelin reached Phase 2 then was discontinued in IBS-related indications. The blend itself has no published combination pharmacology.
The pharmacological rationale is convergent stimulation of pituitary GH release through two receptor pathways — tesamorelin via the GHRH receptor and ipamorelin via the ghrelin (GHS-R1a) receptor. In animal pharmacology the combination of GHRH agonist plus GHS-R1a agonist produces synergistic GH peaks compared with either alone; the principle is well-established in the secretagogue literature, though no published human study has tested this specific combination.
None for the combination. Tesamorelin component evidence is tier 1 (FDA-approved for visceral fat reduction in HIV lipodystrophy via Phase 3 trials). Ipamorelin component evidence is tier 4 — Phase 2 trials in postoperative ileus and orthopedic recovery were not conclusive enough to support approval; development was discontinued.
No combined safety database. Each component has its own profile (tesamorelin: injection-site reactions, transient IGF-1 elevation, glucose-tolerance changes; ipamorelin: short-term safety in Phase 2 acceptable but no long-term human data). Predicting the combined profile from components is inference, not data.
Regulatory status
- FDA status:
- Not FDA-approved
Vendor blend marketing for body-composition or recovery indications is not supported by any published combination trial. The two components have very different half-lives (tesamorelin ~30 min subcutaneous; ipamorelin ~2 h) — pulsatility and dosing schedule for the combination has no published optimisation.